Neurocrine Biosciences In... (NBIX)

Neurocrine (NBIX) Q2 Revenue Jumps 17%

Neurocrine Biosciences' Ingrezza still generates most of its total revenues. This is their blockbuster drug. I also believe Ingrezza is well-positioned for future growth with new label additions, and ...

Neurocrine Biosciences, Inc. (NASDAQ:NBIX ) Q2 2025 Earnings Conference Call July 30, 2025 4:30 PM ET Company Participants n - Corporate Participant Eiry Wyn Roberts - Corporate Participant Strategic ...

Although the revenue and EPS for Neurocrine (NBIX) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Stree...

Neurocrine Biosciences (NBIX) came out with quarterly earnings of $1.06 per share, beating the Zacks Consensus Estimate of $0.98 per share. This compares to earnings of $0.63 per share a year ago.

Investors with an interest in Medical - Drugs stocks have likely encountered both Catalyst Pharmaceutical (CPRX) and Neurocrine Biosciences (NBIX). But which of these two companies is the best option ...

Neurocrine (NBIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Neurocrine's core assets, INGREZZA and Crenessity, can drive strong revenue growth with robust patent protection and significant market underpenetration. The pharma's pipeline is advancing, with multi...

With the notable exceptions of Novo Nordisk A/S NYSE: NVO and Eli Lilly & Co. NYSE: LLY, biotechnology stocks had a rough time attracting investment capital in 2024. Small- and mid-cap biotech stocks ...

Investors with an interest in Medical - Drugs stocks have likely encountered both Catalyst Pharmaceutical (CPRX) and Neurocrine Biosciences (NBIX). But which of these two stocks offers value investors...